Literature DB >> 8590775

Biology of flt3 ligand and receptor.

S D Lyman1.   

Abstract

The flt3 ligand is a member of a small family of growth factors that stimulate the proliferation of hematopoietic cells; other members of this family include Steel factor (also known as mast cell growth factor, stem cell factor, and kit ligand) and colony stimulating factor 1. These proteins function by binding to and activating unique tyrosine kinase receptors. Expression of the flt3 receptor is primarily restricted among hematopoietic cells to the most primitive progenitor cells. The flt3 ligand is similar to Steel factor in that both proteins stimulate the proliferation of early progenitor or stem cells. Neither of these factors has much proliferative activity on its own, but each factor can synergize with a wide range of other colony stimulating factors and interleukins (ILs) to stimulate proliferation. One major difference between the two factors appears to be their effect on mast cells, which Steel factor stimulates but flt3 ligand does not. Although flt3 ligand and Steel factor each act on early hematopoietic cells, differences in their activities suggest that they are not redundant and both are required for normal hematopoiesis. There are a number of clinical settings in which the flt3 ligand may potentially prove quite useful.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590775     DOI: 10.1016/0925-5710(95)00389-a

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

Review 1.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 2.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

3.  Differentiating neurons derived from human umbilical cord blood stem cells work as a test system for developmental neurotoxicity.

Authors:  Mahendra P Kashyap; Vivek Kumar; Abhishek K Singh; Vinay K Tripathi; Sadaf Jahan; Ankita Pandey; Ritesh K Srivastava; Vinay K Khanna; Aditya B Pant
Journal:  Mol Neurobiol       Date:  2014-05-24       Impact factor: 5.590

4.  Polymicrobial Sepsis Diminishes Dendritic Cell Numbers and Function Directly Contributing to Impaired Primary CD8 T Cell Responses In Vivo.

Authors:  Robert K Strother; Derek B Danahy; Dmitri I Kotov; Tamara A Kucaba; Zeb R Zacharias; Thomas S Griffith; Kevin L Legge; Vladimir P Badovinac
Journal:  J Immunol       Date:  2016-10-26       Impact factor: 5.422

5.  Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells.

Authors:  Carlos E Marroquin; Jennifer A Westwood; Rejean Lapointe; Arnold Mixon; John R Wunderlich; Dania Caron; Steven A Rosenberg; Patrick Hwu
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

Review 6.  Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.

Authors:  Yun Chen; Yihang Pan; Yao Guo; Wanke Zhao; Wanting Tina Ho; Jianlong Wang; Mingjiang Xu; Feng-Chun Yang; Zhizhuang Joe Zhao
Journal:  Stem Cell Investig       Date:  2017-06-02

7.  Polyomavirus-infected dendritic cells induce antiviral CD8(+) T lymphocytes.

Authors:  D R Drake; J M Moser; A Hadley; J D Altman; C Maliszewski; E Butz; A E Lukacher
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo.

Authors:  P S Koka; B D Jamieson; D G Brooks; J A Zack
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

9.  RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels.

Authors:  Anne L Astier; Gaëlle Beriou; Thomas M Eisenhaure; Stephen M Anderton; David A Hafler; Nir Hacohen
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

10.  The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up.

Authors:  Santosh K Sanganalmath; Adam B Stein; Yiru Guo; Sumit Tiwari; Greg Hunt; Robert J Vincent; Yiming Huang; Arash Rezazadeh; Suzanne T Ildstad; Buddhadeb Dawn; Roberto Bolli
Journal:  J Mol Cell Cardiol       Date:  2009-07-16       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.